Clinical trials
MGMT-Methylated Glioblastoma clinical trials
Below are recruiting mgmt-methylated glioblastoma clinical trials, each written for real people, not researchers. We’re tracking 5 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06991101RecruitingPhase 2
Ruxolitinib with radiation and chemo for new glioblastoma
This trial tests adding ruxolitinib, a targeted drug, to the standard radiation and chemotherapy for newly diagnosed glioblastoma. It aims to see if this combination helps people live longer without their cancer growing.
Miami, FloridaAges 18 years+ - NCT05432804RecruitingPhase 1/Phase 2
Selinexor added to temozolomide for recurring brain glioblastoma
This trial studies whether adding selinexor to the standard chemotherapy temozolomide (with radiation) can better treat glioblastoma that has come back after prior treatment. If you meet specific tumor, health, and lab requirements, the goal is to slow tumor growth or improve symptoms.
Phoenix, ArizonaAges 18 years+ - NCT06419946RecruitingPhase 3
Lomustine study for MGMT methylated glioblastoma
This trial tests adding lomustine chemotherapy to standard treatment for people with a specific type of glioblastoma that has a methylated MGMT gene. It aims to see if this combination helps control the tumor better and improves survival.
GrazAges 18–70 - NCT06504381RecruitingPhase 1/Phase 2
DB107 and radiation therapy for high-grade glioma
This trial tests a new two-part treatment (DB107-RRV and DB107-FC) combined with radiation, with or without the chemotherapy drug temozolomide, for people with newly diagnosed high-grade glioma. It aims to see if this approach is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06649851RecruitingPhase 2
G-CSF to reduce side effects during glioblastoma treatment
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
Boston, MassachusettsAges 18 years+
Hear when a new MGMT-Methylated Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mgmt-methylated glioblastoma?
- Yes. Clin2 currently lists 5 recruiting mgmt-methylated glioblastoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mgmt-methylated glioblastoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mgmt-methylated glioblastoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.